Eisai presents promising Phase II trial results for tau antibody E2814 in Alzheimer's disease.

Eisai, a Japanese pharmaceutical company, presented findings on its investigational tau antibody, E2814, at the CTAD conference. The study showed significant reductions in tau protein levels in patients with Dominantly Inherited Alzheimer's Disease, suggesting E2814 may inhibit tau propagation and accumulation. Eisai has launched a Phase II clinical trial for early Alzheimer's patients to assess the safety and efficacy of E2814 alongside lecanemab, aiming to improve patient outcomes.

October 31, 2024
21 Articles

Further Reading